Acrivon Therapeutics Inc (ACRV)
7.55
+0.15
(+2.03%)
USD |
NASDAQ |
Jun 12, 16:00
7.55
0.00 (0.00%)
Pre-Market: 20:00
Acrivon Therapeutics EPS Diluted (Quarterly): -0.73 for March 31, 2024
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -0.73 |
December 31, 2023 | -0.87 |
September 30, 2023 | -0.66 |
June 30, 2023 | -0.63 |
March 31, 2023 | -0.58 |
December 31, 2022 | -0.80 |
Date | Value |
---|---|
September 30, 2022 | -0.489 |
June 30, 2022 | -0.4508 |
March 31, 2022 | -0.5593 |
December 31, 2021 | -0.3364 |
September 30, 2021 | -0.189 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-0.87
Minimum
Dec 2023
-0.189
Maximum
Sep 2021
-0.5722
Average
-0.58
Median
Mar 2023
EPS Diluted (Quarterly) Benchmarks
MyMD Pharmaceuticals Inc | -5.14 |
Vincerx Pharma Inc | -0.58 |
Heron Therapeutics Inc | -0.02 |
GlycoMimetics Inc | -0.17 |
Immunic Inc | -0.30 |
EPS Diluted (Quarterly) Related Metrics
Net Income (Quarterly) | -16.49M |
Total Expenses (Quarterly) | 17.67M |
Enterprise Value | 123.15M |
Earnings Yield | -38.28% |